Education

Eastern Washington University 1980 – 1984 Nursing BS – 1984

University of Pennsylvania 1990 – 1991 Post Baccalaureate
Pre-Med

Medical College of Pennsylvania 1991 – 1995 Medicine MD – 1995

University of Iowa 2002 – 2004 Epidemiology
MS - 2004

Post-Graduate Education

University of Iowa 1995-1999 Residency Certificate
Hospitals and Clinics Obstetrics & Gynecology

University of Iowa 2002-2004
K-30 Fellow, Clinical Investigation
Certificate - 2004

Certification

American Board of Obstetrics and Gynecology 900167

Licensure

Iowa

Professional and Academic Positions

• 1999-2002
  Staff, Obstetrician/Gynecologist
  Group Health Cooperative
  Olympia, Washington
• 2002-2005
  Associate, Department of Obstetrics and Gynecology
  University of Iowa Hospitals and Clinics
  Iowa City, Iowa
• 2005 to present
  Assistant Professor, Department of Obstetrics and Gynecology
  University of Iowa Hospitals and Clinics
  Iowa City

Areas of Research Interest

Lower Genital Tract Diseases
Vulvovaginal Diseases
Vulvodynia

Current Projects

Federal/NIH/CDC

Primary-Investigator - K23 HD45769-01: Mentored Patient-Oriented Research Career Development Award. Vulvar Disease and Bladder and Bowel Symptoms. National Institute of Child Health and Development.

Institutional

General Clinical Research Center Pilot Grant. Vulvar Pain: Treatment trial using gabapentin.

Clinical Trials

1547-851B-62 A Randomized, USA and Canada, Multicenter, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection.

V503-001. A Randomized, International, Double-Blinded, Controlled with Gardasil, Dose-Ranging, Tolerability, Immunogenicity, and Efficacy Study of a Second Generation Human Papillomavirus L1 Virus-Like Particle Vaccine administered to 16-26 year old women.

A randomized, worldwide, placebo-controlled, double-blind, study to investigate the safety, immunogenicity and efficacy on the incidence of HPV 16/18 related CIN 2/3 or worse of the Quadrivalent HPV (6,11,16,18) L1 Virus Like Particle Vaccine in 16-23 year old Women – the Future II Study.

A Phase III, double blind, randomized, controlled, multicenter study to evaluate the efficacy of HPV 16/18 VLP/ASO4 Vaccine.

A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gDAlum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.

HPV-015: A phase III, double-blind, randomized, controlled study to evaluate the safety, immunogenicity and efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above.

Co-Investigator - 1485-R851: Phase I, Rising Multiple-Dose Safety, Pharmacokinetic, and Pharmacodynamic Study of R-851 Gel Delivered Intravaginally to Female Subjects with Cervical Dysplasia. 3M Pharmaceuticals. 2003-2004.

Co-Investigator - A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gDAlum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative. National Institute of Allergy and Infectious Diseases/GlaxoSmithKline. 2003-2004.